Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Translation Inhibition Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LARS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LARS2 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. HEK293 or E. coli expressed options. |
View LARS2 Products |
| Gene Delivery | LARS2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and mitochondrial localization assays. |
View LARS2 Products |
| Benchmark Ab | Anti-LARS2 Recombinant Antibody Recombinant positive control for expression validation and IHC/Western Blot assays. |
View LARS2 Products |
| Validator | LARS2 siRNA Set For target knockdown verification and phenotypic target validation. |
View LARS2 Products |
| Related Target A | LARS1 Cytoplasmic homolog. Essential for off-target selectivity screening to prevent systemic toxicity. |
View LARS1 Products |
| Related Target B | YARS2 Mitochondrial tyrosyl-tRNA synthetase. Key partner for profiling mitochondrial translation pathway selectivity. |
View YARS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target toxicity from cytoplasmic LARS1 inhibition | Parallel availability of highly purified LARS2 and LARS1 proteins for comparative selectivity assays. |
| In vitro enzymatic assay reproducibility | Sequence-verified recombinant proteins with theoretical molecular weight confirmation and consistent batch-to-batch purity (>95%). |
| Lack of Controls | Sequence-defined benchmark recombinant antibodies included for reliable assay baselines. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for orthogonal genetic knockdown validation. |
Live LARS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LARS2 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum mitochondrial inhibitors to targeted small molecule inhibitors of mitochondrial aminoacyl-tRNA synthetases. As first-generation therapies targeting mitochondrial translation reach the clinic, the next wave of R&D is targeting cancer stem cell (CSC) metabolic vulnerabilities and drug-resistant solid tumors.
LARS2 (mitochondrial leucyl-tRNA synthetase) is a critical nuclear-encoded mitochondrial enzyme. Because cancer cells frequently overexpress mitochondrial translation machinery to sustain rapid oxidative phosphorylation (OXPHOS), selective inhibition of LARS2 has emerged as a highly promising strategy to starve cancer cells of energy without disrupting cytoplasmic protein synthesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Oncology-focused Biotechs, Academic Consortia | Nasopharyngeal Carcinoma, Breast Cancer, Ovarian Cancer | Enzymatic Selectivity Assay (Need high-purity LARS2 vs LARS1 recombinant proteins) |
| Gene Therapy / RNAi | Rare Disease Therapeutics Developers | Perrault Syndrome (LARS2 mutations), Mitochondrial Myopathies | Functional Rescue Validation (Need Lentivirus for stable expression and siRNA for knockdown) |